Matt Browne's practice focuses on transactional and general corporate matters, with Matt typically serving as his client’s first point of contact at Cooley for all matters and regularly working with them on mergers and acquisitions, public and private securities offerings, public company reporting and disclosure issues, corporate governance matters and other commercial matters. Matt also has expertise in the drug royalty space, having advised clients on numerous drug royalty transactions involving many different transaction structures and with aggregate proceeds in excess of $2.3 billion.

Download full bio 


  • Billtrust to Combine With South Mountain, a Special Purpose Acquisition Company, at $1.3 Billion Value 

  • Oberland Capital in financing of Agenus 

  • AcelRx sale of Zalviso® royalties to PDL BioPharma  

  • Renovate America Series F financing  

  • TPG Special Situations Partners purchase of Kadcyla® royalties from ImmunoGen  

  • View all


  • Harvard Law School
    JD, cum laude, 1995

  • Yale University
    BA, with distinction in two majors, Economics and Political Science
    summa cum laude, Phi Beta Kappa, 1990

Admissions & Credentials


New York


  • American Bar Association

  • New York State Bar Association

Rankings & Accolades

    The Best Lawyers in America – Corporate Law